CONNECTING Healthcare EXPERTISE

THE CLINICIAN EXCHANGE is a virtual exchange designed to pair specific clinical skillsets with specific industry initiatives.

EXCHANGE YOUR EXPERTISE

Learn how you can unlock the power of your expertise and experience to impact the healthcare industry in ways never before imagined

REGISTER NOWLEARN MORE

EXTEND, EXCEL…EXPLORE THE EXCHANGE

Learn how you can cost-effectively multiply your sales, education and R&D resources in an instant

REGISTER NOWLEARN MORE

COMMUNITY PORTAL

IN THE NEWS

CLINICIAN NEWS

Provided by: Medscape

HEALTHCARE SUPPLIER NEWS

Adding precision to multiple myeloma treatments with DNA sequencing: ASH

Published: Mon, 11 Dec 2017 14:04:54 +0000
At the annual American Society of Hematology (ASH) meeting, oncologists at the Dana-Farber Cancer Institute demonstrated how simple blood tests may make it possible to use DNA sequencing to track how multiple myeloma is progressing in individual patients—and whether they're becoming resistant to the therapies they’re given.

Syros tanks on single-digit response rate in AML, MDS trial 

Published: Mon, 11 Dec 2017 13:33:07 +0000
Syros Pharmaceuticals has emerged from the weekend of ASH data drops in a battered state after it was unable to put a positive spin on an initial look at phase 2 data. The clinical trial recorded one partial or complete response among the 48 evaluable patients, wiping 50% off Syros’ stock.

Bluebird and Celgene’s CAR-T hits the mark in myeloma

Published: Mon, 11 Dec 2017 12:29:31 +0000
Patients with highly advanced multiple myeloma have seen spectacular results with Bluebird Bio and Celgene’s CAR-T therapy bb2121; the disease was pushed into remission in more than half of those treated.
Displaying results 7-9 (of 25)
 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 

HAVE A QUESTION?

 Security code
1-800-4-the-clinx

Clinician Owned and Veteran Owned

copyright 2017 THE CLINICIAN EXCHANGE. Privacy Policy
Top